Email Print this page Bookmark this page

Writing LACRISERT®

LACRISERT® Packaging

LACRISERT® is a translucent, rod-shaped ophthalmic insert made up of only 5 mg of hydroxypropyl cellulose.1

A single package of LACRISERT® contains 60 inserts, each individually wrapped in unit-dose aluminum blister packs for sanitary purposes. The package also includes illustrated instructions, 2 flexible applicators for inserting LACRISERT®, and a plastic storage container to store the applicators for reuse.1

If your patient administers LACRISERT® in each eye once daily, each package will cover 1 month of use.

LACRISERT® Prescription

Valeant is committed to ensuring that supplies of LACRISERT® are available for your patients throughout the United States and in many countries worldwide.

Simply complete your prescription form as pictured below and have your patient drop it off at any local pharmacy.

Indications and Usage

LACRISERT® is indicated in patients with moderate to severe Dry Eye syndromes, including keratoconjunctivitis sicca. LACRISERT® is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. LACRISERT® is also indicated for patients with exposure keratitis, decreased corneal sensitivity, and recurrent corneal erosions.

Important Safety Information

LACRISERT® is contraindicated in patients who are hypersensitive to hydroxypropyl cellulose. Instructions for inserting and removing LACRISERT® should be carefully followed. If improperly placed, LACRISERT® may result in corneal abrasion. Because LACRISERT® may cause transient blurred vision, patients should be instructed to exercise caution when driving or operating machinery. Patients should be cautioned against rubbing the eye(s) containing LACRISERT®.

The following adverse reactions have been reported, but were in most instances, mild and temporary: transient blurring of vision, ocular discomfort or irritation, matting or stickiness of eyelashes, photophobia, hypersensitivity, eyelid edema, and hyperemia.

Reference: 1. Lacrisert [prescribing information]. Lawrenceville, NJ: Aton Pharma, Inc; 2007.

sample request using Lacrisert video patient tip sheet
©2012 Valeant Ophthalmics, a division of Valeant Pharmaceuticals North America LLC          Bridgewater, NJ 08807